Literature DB >> 30633038

Epidemiology of intrahepatic, perihilar, and distal cholangiocarcinoma in the French population.

Aimen Al Mahjoub1,2,3, Véronique Bouvier1,4,3, Benjamin Menahem1,2,3, Céline Bazille5, Audrey Fohlen6,7, Arnaud Alves1,2,3, Andrea Mulliri1,2, Guy Launoy1,4,3, Jean Lubrano1,2,3.   

Abstract

OBJECTIVES: The objective of this study was to investigate the differences between cholangiocarcinoma (CC) subtypes in terms of incidence rate, clinical presentation, management and survival by applying a stable anatomical classification in a population-based study. PATIENTS AND METHODS: Cancer data for the period 2000-2012 were obtained from a specialized digestive cancer registry in the Department of Calvados, France. Patients' files were checked, and the diagnosis was verified by two hepatobiliary surgeons. This approach prevents classifying perihilar cholangiocarcinoma (PHCC) as intrahepatic cholangiocarcinoma (ICC), thereby allowing an accurate estimation of their respective epidemiological characteristics.
RESULTS: A total of 320 patients with CC were included. ICC represented 41% (130), whereas PHCC and distal cholangiocarcinoma represented 36 (116) and 23% (74), respectively. The mean age at the time of diagnosis differed significantly between the three subtypes (P<0.05). ICC was discovered accidently more frequently than PHCC, which was associated significantly with clinical symptoms. No change in the incidence or survival rates of CC subtypes were noticed, except for PHCC, in which female individuals had a significantly shorter median and 5-year survival rate of 0% (P<0.05).
CONCLUSION: The frequency of PHCC is overestimated in the literature. The anatomical reclassification of CC subtypes shows the stability of their incidence and survival rates. Considering ICC and PHCC as two different entities implies the need to assign a specific topographic code for PHCC.

Entities:  

Year:  2019        PMID: 30633038     DOI: 10.1097/MEG.0000000000001337

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  7 in total

1.  Prognostic impact of lymph node parameters in distal cholangiocarcinoma after pancreaticoduodenectomy.

Authors:  Shaocheng Lyu; Lixin Li; Xin Zhao; Zhangyong Ren; Di Cao; Qiang He
Journal:  World J Surg Oncol       Date:  2020-10-08       Impact factor: 2.754

2.  Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland.

Authors:  Nina Barner-Rasmussen; Eero Pukkala; Kishor Hadkhale; Martti Färkkilä
Journal:  United European Gastroenterol J       Date:  2021-09-17       Impact factor: 4.623

3.  Comparison of oncologic outcomes of extrahepatic cholangiocarcinoma according to tumor location: perihilar cholangiocarcinoma versus distal bile duct cancer.

Authors:  Jung Min Lee; Hongbeom Kim; Hee Ju Sohn; Yoo Jin Choi; Jae Seung Kang; Youngmin Han; Wooil Kwon; Jin-Young Jang
Journal:  Ann Surg Treat Res       Date:  2022-02-04       Impact factor: 1.859

4.  Patient healthcare trajectories of intrahepatic cholangiocarcinoma in France: A nationwide retrospective analysis.

Authors:  Cindy Neuzillet; Corinne Emery; Clément Teissier; Stéphane Bouée; Astrid Lièvre
Journal:  Lancet Reg Health Eur       Date:  2022-02-05

5.  Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review.

Authors:  Peiyi Xie; Lei Guo; Bo Zhang; Yongfeng Xu; Qi Song; Hongcheng Shi; Qinghai Ye; Hui Li; Yongsheng Xiao
Journal:  Front Oncol       Date:  2022-08-03       Impact factor: 5.738

6.  Secular trends of intrahepatic cholangiocarcinoma in a high endemic area: A population-based study.

Authors:  Chun-Ru Lin; Yu-Kwang Lee; Chun-Ju Chiang; Ya-Wen Yang; Hung-Chuen Chang; San-Lin You
Journal:  World J Gastroenterol       Date:  2022-07-28       Impact factor: 5.374

Review 7.  Significant Response to Camrelizumab Plus Targeted Drugs in Recurrent Intrahepatic Cholangiocarcinoma: a Case Report and Literature Review.

Authors:  Peixin Huang; Yingting Zhou; Yi Chen
Journal:  J Gastrointest Cancer       Date:  2021-07-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.